Rituximab in the treatment of autoimmune haematological disorders.

Rituximab in the treatment of autoimmune haematological disorders. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Rituximab in the treatment of autoimmune haematological disorders. Abstract Text:

Current treatment regimens for haematological autoimmune diseases are relatively non-selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B-cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews data supporting the use of rituximab--an anti-CD20 monoclonal antibody that specifically depletes B cells--in four key autoimmune haematological disorders: idiopathic thrombocytopenic purpura (ITP); autoimmune haemolytic anaemia (AIHA); acquired haemophilia; and thrombotic thrombocytopenic purpura (TTP). Although treatment of ITP, AIHA, acquired haemophilia and TTP with rituximab is still relatively uncommon, results from case series and small phase II trials indicate that patients of all ages can respond to rituximab, irrespective of the number or type of prior treatments that they have received. Moreover, patients with these diseases receiving rituximab experienced predominantly mild adverse events, with only a few serious adverse events reported. These data suggest that rituximab provides an effective and well-tolerated alternative treatment option for patients with ITP, AIHA, acquired haemophilia and TTP, many of whom have limited treatment choices.

Rituximab in the treatment of autoimmune haematological disorders. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Rituximab in the treatment of autoimmune haematological disorders. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: British journal of haematology

VOLUME: 141

Page Numbers: 149-69

Journal Abbreviation: Br. J. Haematol.

ISSN: 1365-2141

DAY: 3

MONTH: 03

YEAR: 2008

Rituximab in the treatment of autoimmune haematological disorders. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372544

Rituximab in the treatment of autoimmune haematological disorders. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Rituximab in the treatment of autoimmune haematological disorders. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Rituximab in the treatment of autoimmune haematological disorders.

AFFILIATION: St Michael's Hospital, University of Toronto, Toronto, ON, Canada. garveyb@smh.toronto.on.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Rituximab in the treatment of autoimmune haematological disorders Related Publications

• Asymmetries of long-latency intracortical inhibition in motor cortex and handedness.
• Atmospheric particulate absorption and black carbon measurement.
• Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis.
• Biological responses to contrasting hydrology in backwaters of upper Mississippi river navigation pool 25.
• Calcification of the mitral annulus fibrosus.
• Current management issues of childhood and adult immune thrombocytopenic purpura (ITP).
• Depression and smoking across 25 years of the Normative Aging Study.
• Dextrostix-Eyetone in the insulin hypoglycaemia test.
• Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects.
• Efficacy of gentamicin in treatment of chronic urinary-tract infections.
• Endogenous vasopressin and renin-angiotensin systems support blood pressure after epidural block in humans.
• Enhancement of a Lewis acid-base interaction via solvation: ammonia molecules and the benzene radical cation.
• Multiple venous thromboses.
• NR4A orphan nuclear receptors modulate insulin action and the glucose transport system: potential role in insulin resistance.
• Nephelometer optical response model for the interpretation of atmospheric aerosol measurements.
• New retractors for use in vaginal ureterolithotomy.
• Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.
• Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women.
• Preliminary nephrostomy preparatory to secondary nephrectomy.
• Pseudohypoparathyroidism; case report.
• Return of alosetron.
• Rituximab in the treatment of autoimmune haematological disorders.
• Survival in cancer of the prostate.
• The dental assistant's role in integrating digital impression technology in the dental practice.
• The effect of insulin on expression of genes and biochemical pathways in human skeletal muscle.
• Tips for reducing workers' heat load.
• Urolithiasis: a review of three hundred cases.